Abstract | OBJECTIVE: RESEARCH DESIGN AND METHODS: We followed a cohort of 66 778 female patients with diabetes for a maximum of 12 years (median 6 years). We examined breast, endometrial, and ovarian cancer risk, and the composite cancer risk. We examined drug categories using pharmacy records: metformin only; metformin combination regimens; non- metformin regimens; and non-users. We used χ(2) analyses to examine categorical variables. We conducted multivariable Cox regression models with time-dependent drug use status. RESULTS: Women who used metformin combination regimens versus metformin only had a 15% lower breast cancer risk (adjusted HR=0.85, 95% CI 0.69 to 1.04). After stratifying by glycated hemoglobin (HbA1c), the association attenuated in those who had poorly controlled HbA1c (adjusted HR=1.06, 95% CI 0.73 to 1.55). Given the small numbers of ovarian and endometrial cancer outcomes, we examined these as a composite. The risk of all cancers combined was similar in those who used metformin combination regimens versus metformin only (adjusted HR=0.92, 95% CI 0.78 to 1.10). We found no significant differences for breast cancer or all cancers combined when we compared risks in non- metformin users versus metformin only users. CONCLUSIONS:
|
Authors | Diana Soffer, Jiaxiao Shi, Joanie Chung, Joanne E Schottinger, Lauren P Wallner, Rowan T Chlebowski, Scott E Lentz, Reina Haque |
Journal | BMJ open diabetes research & care
(BMJ Open Diabetes Res Care)
Vol. 3
Issue 1
Pg. e000049
( 2015)
ISSN: 2052-4897 [Print] England |
PMID | 25664181
(Publication Type: Journal Article)
|